Berberine is one of 215 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
174 competitors in Schizophrenia
Berberine
Ozempic
Resotran
Inapsine
Depakote
Ibrance
Lunesta
Luvox
Catapres
Rapamune
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details